Heineken N.V. reports the progress of transactions under its current
share buyback programme

Amsterdam, 28 September 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 21 September 2026 up to and including 25 September 2026 a total of 164,417 shares were repurchased on exchange at an average price of € 71.27. During the same period, 164,949 shares were repurchased from Heineken Holding N.V.

Up to and including 25 September 2026, a total of 7,847,104 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 556,849,996 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media   Investors
Christiaan Prins   Tristan van Strien
Director of Global Communication   Global Director of Investor Relations
Marlie Paauw   Lennart Scholtus / Isabelle van Rongen
Global Media Lead   Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com   E-mail: investors@heineken.com
Tel: +31-20-5239355   Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

Partnership Expands Flyte’s Growing Presence Across Entertainment, Fashion, Hospitality, Sports and Premium Destination Travel

2026 Flyte Breakthrough Awards will Honor Anthony Ippolito, Star of Amazon MGM Studios’ “I Play Rocky,” Rosalind Eleazar of Chris Rock’s “Misty Green,” and A24’s Jordan Firstman

Flyte Brand to be Prominent Throughout this Prestigious Eleven-Day Festival Bringing Together Leading Actors, Filmmakers, Executives and Audiences from Around the World

FORT MILL, S.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”), today announced it has established a partnership with the Hamptons International Film Festival (“HIFF”), in which Flyte has been named the ‘Official Air Travel Partner’ of the 34th annual HIFF taking place October 2 through October 12, 2026.

As Official Air Travel Partner, Flyte will have a prominent presence throughout the eleven-day festival, which brings together leading filmmakers, actors, artists, executives, and audiences from around the world for screenings, conversations, and events across the East End.

As a Lead Sponsor of the festival, Flyte’s presence extends across several of HIFF’s marquee programs. Flyte is also a sponsor of World Cinema Narrative, the Festival’s largest narrative section, featuring a wide-ranging slate of international films including Coward, Minotaur, Tender Loving Care and many more.

Additionally, Flyte will sponsor the Festival’s 2026 Breakthrough Honors, continuing a longstanding program with a history of recognizing emerging talent that has gone on to become some of the most prominent names in film and entertainment. The 2026 Flyte Breakthrough Award recipients include:

  • Anthony Ippolito, who will receive a Flyte Breakthrough Performer Award in connection with I Play Rocky, the festival’s Opening Night film. Ippolito portrays Sylvester Stallone in the upcoming Amazon MGM Studios film.
  • Rosalind Eleazar, who will receive a Flyte Breakthrough Performer Award for her performance in Misty Green, written and directed by Chris Rock.
  • Jordan Firstman, who will receive the Flyte Breakthrough Director Award for Club Kid, an A24 release that Firstman wrote, directed and stars in.

The Festival’s Breakthrough program has previously recognized talent including Emma Stone, Mahershala Ali, Jessica Chastain, Lupita Nyong’o, Adam Driver, Brie Larson, Timothée Chalamet, Michael B. Jordan, Oscar Isaac and Emily Blunt.

“The Hamptons International Film Festival has become an important part of the cultural fabric of the East End, and we are proud to participate as its Official Air Travel Partner,” said Marc Sellouk, Founder of Flyte. “Flyte has developed a meaningful presence in the Hamptons, and this partnership feels like a natural extension of that. We are especially proud to lend the Flyte name to the Breakthrough Awards and recognize Anthony, Rosalind and Jordan alongside a program with an extraordinary history of talent.”

A Natural Connection to the Hamptons

As a natural showcase for the advantages of regional private aviation, the Hamptons have become an important market for Flyte.

Flyte operates a standardized fleet of Cirrus Vision Jets designed for short-haul private travel. Through its technology-enabled platform, customers can access private aviation through a streamlined digital experience, bringing greater simplicity and transparency to a travel category that historically had been complex to navigate.

For travel between the New York metro area and the East End, that combination is particularly relevant. What can otherwise require hours by car becomes a far more efficient journey by air, enabling travelers to spend more time at their destination and less time getting there. Furthermore, many of the smaller airports serviced by Flyte, which lack scheduled commercial air service, have far less surrounding traffic, easy ride-share access and more convenient parking than larger airports. The result is a unique expression of private aviation: not simply a solution for long-distance travel, but an increasingly seamless way to move between the places that matter.

“The most interesting part of regional private aviation is how naturally it can fit into someone’s life when the experience is simple,” Mr. Sellouk continued. “The aircraft, technology, booking platform and the customer-facing experience all must work together seamlessly. That is what we have built at Flyte, and the Hamptons exemplify this newly available and surprisingly affordable premium experience.”

A Growing Presence Across Culture and Travel

Whether traveling to the Hamptons for the film festival, New York for fashion week, a golf destination for the weekend, or The Bahamas for a resort stay, Flyte has built a private aviation platform designed around the way its customers actually travel.

The Company’s combination of a standardized aircraft fleet, technology-enabled booking experience and expanding network makes regional private aviation considerably more seamless while preserving the service, privacy and luxury experience expected from private travel.

About HamptonsFilm

HamptonsFilm, home of the Hamptons International Film Festival, was founded in 1992 to celebrate the art of film and introduce audiences to a diverse spectrum of international films and filmmakers. The organization presents the annual Hamptons International Film Festival along with year-round programming supporting filmmakers, artists and film culture.

About Flyte

Flyte is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the United States and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster, safer, and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
IR@CatheterPrecision.com

Transaction Includes Sale-Leaseback of 17 Aircraft with Strategic Capital’s Second Investment Vehicle and Acquisition of 10 Off-Lease Aircraft to Support FTAI’s Aerospace Products Business

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI; the “Company” or “FTAI”) today announced the acquisition of 27 Boeing 737-700 aircraft from WestJet. The acquisition marks one of FTAI’s largest aircraft transactions to date.

Under the transaction, FTAI’s 2026 SPV, the second investment vehicle of the Company’s Strategic Capital business, acquired 17 Boeing 737-700 aircraft on lease to WestJet in a sale-leaseback, and FTAI acquired 10 off-lease Boeing 737-700 aircraft to support its Aerospace Products business.

The 2026 SPV was formed to acquire on-lease, mid-life 737NG and A320ceo aircraft and follows the 2025 SPV, FTAI’s inaugural Strategic Capital vehicle, which raised $2.0 billion of equity commitments and has committed approximately $6.0 billion of total capital across more than 300 aircraft. This transaction highlights FTAI’s position as a differentiated buyer of mid-life narrowbody aircraft, combining aircraft ownership through its Strategic Capital vehicles with its leading engine maintenance capabilities.

The 10 off-lease aircraft will support FTAI’s Aerospace Products business by expanding the Company’s supply of CFM56-7B engines and modules available to its Maintenance, Repair and Exchange customers.

“We are pleased to expand our relationship with WestJet through this transaction,” said David Moreno, President at FTAI. “It demonstrates how our Strategic Capital and Aerospace Products businesses work together to offer airlines comprehensive fleet solutions, from sale-leaseback capital for in-service aircraft to a flexible exit for aircraft transitioning out of the fleet. For Aerospace Products, the retiring aircraft will add CFM56-7B engines and modules to the exchange pool to support our customers’ maintenance requirements.”

“This 27-aircraft transaction is a strategic milestone that officially marks the start of our retirement of our 737-700 fleet. We’re pleased to partner with FTAI Aviation Ltd. to make this happen, and we look forward to building on this relationship for future opportunities,” said Mike Scott, WestJet Group Executive Vice-President and Chief Financial Officer.

McGuireWoods served as counsel to FTAI and BD&P served as counsel to WestJet in connection with the transaction.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the expected benefits of the transaction, the 2026 SPV’s acquisition plans and deployment of capital, the Company’s ability to perform engine maintenance for the leased aircraft, and the expected contribution of the acquired aircraft and engines to the Company’s Aerospace Products business. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, many of which are beyond the Company’s control. The Company can give no assurance that its expectations will be attained and such differences may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. For a discussion of some of the risks and important factors that could affect such forward-looking statements, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the Company’s website (www.ftaiaviation.com). In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements. Such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in events, conditions, or circumstances on which any statement is based. This release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Nothing on the Company’s website is included or incorporated by reference herein.

About FTAI

FTAI combines advanced turbine technology and asset ownership to power the world’s most essential markets. Additional information is available at https://www.ftaiaviation.com.

For further information, please contact:

FTAI:
Charlie Arestia
Investor Relations
(646) 276-4418
ir@ftaiaviation.com

Media:
Tim Lynch / Kelly Sullivan
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat

LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). In the MN-001 group, reductions in serum triglycerides (TG), increases in serum high-density lipoprotein cholesterol (HDL-C) and HDL particle concentration (HDL-P), and a numerical trend toward improvement in liver fat and body weight were observed. MN-001 demonstrated a generally favorable safety and tolerability profile.

Study Overview

MN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated with T2DM. The treatment period was 24 weeks.

Key Results

  • Serum TG: At Week 24, mean serum TG decreased from baseline by 45.8 mg/dL (21.78%) in the MN-001 group and by 14.4 mg/dL (6.97%) in the placebo group. Thus, the mean decrease was 31.4 mg/dL greater with MN-001 than with placebo (p=0.113). At Week 4, mean serum TG decreased from baseline by 54.7 mg/dL (26.05%) in the MN-001 group and by 23.8 mg/dL (11.54%) in the placebo group. The mean decrease was 30.96 mg/dL greater with MN-001 than with placebo, and this difference was statistically significant (p=0.015).
  • Liver fat: At Week 24, the mean controlled attenuation parameter (CAP) score measured by FibroScan® decreased from baseline by 14.1 dB/m (4.24%) in the MN-001 group and by 4.3 dB/m (1.27%) in the placebo group. Thus, the mean decrease was 9.7 dB/m greater with MN-001 than with placebo; however, this difference was not statistically significant (p=0.2438).
  • HDL-C: At Week 24, mean HDL-C increased by 3.3 mg/dL (8.39%) in the MN-001 group but decreased by 2.4 mg/dL (6.23%) in the placebo group. The difference between the MN-001 and placebo groups was 5.7 mg/dL and was statistically significant (p=0.0048).
  • HDL-P: At Week 24, mean HDL-P increased by 3.62 µmol/L (11.80%) in the MN-001 group but decreased by 0.9 µmol/L (3.00%) in the placebo group. The difference between the MN-001 and placebo groups was 4.52 µmol/L and was statistically significant (p=0.018).
  • Body weight: At the end of the study, mean body weight decreased by 4.91 lb (2.28%) in the MN-001 group and by 0.55 lb (0.25%) in the placebo group. Thus, the mean decrease in body weight was 4.36 lb greater with MN-001 than with placebo (p=0.082).

Safety and Tolerability

MN-001 was generally safe and well tolerated. Treatment-related adverse events were mild to moderate in severity, and no drug related serious adverse events (SAEs) were reported in the study.

Clinical Significance of the Results

The study demonstrated a statistically significant reduction in serum TG at Week 4 with MN-001 than with placebo. At Week 24, the MN-001 group continued to show a numerical reduction from baseline value, although the difference between the MN-001 and placebo groups were not statistically significant. Statistically significant increases in HDL-C and HDL-P were also observed with MN-001 group while liver fat and body weight showed trends toward improvement. Collectively, these exploratory findings suggest that MN-001 may have beneficial effects across in several metabolic parameters including lipid metabolism, body weight, and liver fat.

The changes in TG, HDL-C, and HDL-P were also consistent with findings from preclinical in-vitro mechanism of action studies and previous MN-001-NATG-201 clinical trial. Together with the clinical findings, these results provide a basis for further evaluation of MN-001 in metabolic and cardiovascular diseases.

Next Steps

This was a proof of concept, exploratory study involving 40 patients. Preliminary review of the topline data indicates that efficacy should be evaluated in a larger study. We will continue detailed analyses of the study data and assess the next stage of clinical development, including the appropriate patient population, endpoints, and sample size.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable, small-molecule compound thought to exert its effects through several mechanisms to produce anti-inflammatory and antifibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is a novel approach to treating fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis, including LOXL2, Collagen Type 1, and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation, including CCR2 and MCP-1. It also inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake. Recent research suggested that MN-002, the major metabolite of MN-001, significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 and ABCG1.

About Type 2 Diabetes Mellitus (T2DM), Dyslipidemia, and Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance, which plays a central role in the development of dyslipidemia—abnormal levels of lipids in the blood. Hypertriglyceridemia (elevated triglycerides) is commonly observed in individuals with T2DM. It results from increased hepatic lipid synthesis and impaired clearance of triglyceride-rich lipoproteins. Hypercholesterolemia, particularly elevated LDL cholesterol and reduced HDL cholesterol, is also frequently seen and contributes to a higher risk of atherosclerosis. Dyslipidemia not only worsens glycemic control but also increases the risk of cardiovascular complications and liver-related conditions such as nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic complication of insulin resistance and is frequently associated with T2DM and dyslipidemia.

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), each with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF), and a second Phase 2 trial in nonalcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Forward-Looking Statements

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com

  • Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets
  • YUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR
  • Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion
  • The Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million
  • Conference call with Zymeworks management today at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) —  Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.

The acquisition adds YUPELRI® (revefenacin) to Zymeworks’ portfolio, providing a durable, recurring source of cash flow to fund the Company’s long-term growth strategy. Through Theravance Biopharma’s collaboration with Viatris, Zymeworks is entitled to a 35% share of net U.S. profits from YUPELRI and royalties on net sales outside the United States. In the first half of 2026, total YUPELRI sales of $133.1 million resulted in collaboration revenue to Theravance Biopharma of $38.4 million.

“Zymeworks is uniquely positioned to create value from the acquisition through our existing R&D and operational infrastructure, including the ability to leverage the acquired Irish tax attributes alongside our ongoing R&D activities in Ireland, opportunities that are not readily available to traditional royalty-focused buyers,” said Scott Platshon, Chief Business Officer at Zymeworks. “We are pleased to welcome the Theravance Biopharma team to Zymeworks and bring together differentiated assets that add meaningful sources of cash flow to our business. We look forward to building on the combined organizations’ strengths as we continue to build a durable, diversified business and work to develop innovative medicines for patients with serious diseases.”

Commercial Organization and Integration

Zymeworks intends to retain the current commercial organization responsible for YUPELRI sales through the hospital channel. The team brings established commercial capabilities and relationships that Zymeworks believes can support continued growth of the product within the combined organization. The Company plans to hire a seasoned pharmaceutical executive with experience building and leading commercial pharmaceutical organizations to lead the commercial operations of Theravance Biopharma.

In addition, Stuart Knight will become Executive Vice President and Chief Information Officer of Zymeworks, where Stuart will guide the Company’s future technology strategy, including continued investment in the Company’s existing AI, machine learning, and data science capabilities. Stuart brings substantial experience in biotech and pharmaceutical companies operating in both the United States and Europe. Stuart will also be joined by Jesse Fecker, Ph.D., J.D., who joins Zymeworks as Vice President, Intellectual Property.

“We are very pleased to have Stuart and Jesse join Zymeworks’ leadership team as they both bring additional experience and capabilities that will be helpful as we execute against our long-term strategic objectives,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Zymeworks also retains ownership of Theravance Biopharma’s research and development assets, which will be evaluated in the context of the Company’s broader pipeline, strategic priorities, and disciplined capital allocation framework. The Company will continue to pursue opportunities to maximize the value of its combined R&D engine through partnerships, collaborations and other strategic structures, including the potential externalization of selected programs where appropriate.

Financial Impact of Theravance Biopharma Acquisition

The acquisition is expected to provide Zymeworks with meaningful and immediate incremental revenue and operating cash flow following closing, including:

  • Mid-teens base-case IRR, supported primarily by growth in YUPELRI revenues and a smaller contribution from VIBATIV®. This base case does not include potential upside contributions from utilization of tax attributes or future R&D or business development opportunities.
  • 25% growth in YUPELRI hospital sales in the second quarter of 2026, supporting continued margin expansion and increasing operating leverage as net sales continue to scale. Hospital channel growth remains a key driver of the product’s continued expansion in the community setting.
  • Acquisition and restructuring-related costs, excluding capitalized costs attributed to the OMERS Life Sciences (OMERS) non-recourse financing, of approximately $25-30 million
  • $2.5 billion of Irish tax attributes, which may provide additional flexibility to generate value from future Irish revenues, IP structuring and potential acquisitions or investments through the Company’s existing Irish R&D operations. No value has been assigned to the utilization of these tax attributes in the transaction valuation or base case IRR, and any future utilization would therefore represent additional upside.
  • Potential $100 million TRELEGY ELLIPTA® milestone payment expected in the first quarter of 2027, assuming milestone conditions met, offsetting cash outlay for the purchase price.

Transaction Details

Under the terms of the merger agreement announced on June 29, 2026, Theravance Biopharma shareholders received $17.00 in cash at closing for each share of Theravance Biopharma common stock.

The acquisition was financed through a $350 million non-dilutive, non-recourse note from OMERS, in which 75% of the YUPELRI profit-share cash flows are contractually assigned to OMERS to service the associated debt obligations. In addition, approximately $217.5 million of existing cash resources of Zymeworks was used to finance the remaining purchase price, after utilizing the available cash acquired from Theravance Biopharma. The Company expects this net investment to be reduced upon receipt of a potential milestone payment related to TRELEGY ELLIPTA of $100 million expected in the first quarter of 2027.

During the one-year period from closing of this transaction, a designee of Theravance Biopharma will seek to potentially license, divest or otherwise monetize ampreloxetine, with no additional resources expected from Zymeworks. The economics of any such transaction will be shared 20/80 between Zymeworks and Theravance Biopharma shareholders.

Following completion of the transaction, Theravance Biopharma’s common stock is no longer listed for trading on the Nasdaq Global Select Market.

Accounting Treatment

The transaction is expected to be accounted for as a business combination. The purchase price will be allocated to the fair value of the net assets acquired and primarily includes rights related to YUPELRI, with any remaining amount recorded as goodwill. YUPELRI is expected to represent the principal identifiable intangible asset and will be amortized over its estimated useful life, generally through the expected loss-of-exclusivity period.

The right to receive a potential milestone payment based on global net sales of TRELEGY ELLIPTA is expected to be recognized as a financial asset at fair value as of the closing date. Assuming the applicable commercial sales milestone is achieved by December 31, 2026, the related milestone payment of $100 million is expected to be collected in the first quarter of 2027. 

The Company also expects to recognize a tax liability due to an uncertain tax position as part of the accounting for the business combination. Upon expiration of the applicable audit period in October 2026, the liability may be reversed, resulting in the recognition of a non-cash income tax benefit in the fourth quarter of 2026.

The Company expects to account for the $350 million non-recourse note issued to OMERS as debt using the prospective effective interest rate method. Until the note is repaid, 75% of the YUPELRI profit-share cash flows will be applied to the payment of principal and interest, with the Company retaining the remaining 25%. Following repayment of the note, the Company will retain 100% of the YUPELRI profit-share cash flows.

The preliminary accounting for the transaction will be reflected in the Company’s consolidated financial statements in its Form 10-Q for the quarter ending September 30, 2026, which is expected to be filed in November 2026.

Updated Financial Guidance for 2026

With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. Food and Drug Administration approval of Ziihera® (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma on August 25, 2026, the Company has provided updated financial guidance utilizing relevant financial metrics that it believes provide a more suitable framework for evaluating operating performance of the business.

“The Company expects total revenue for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions,” stated Kristin Stafford, Chief Financial Officer of Zymeworks. “During 2026, we have been able to access a total of $600 million in non-dilutive financing in the form of non-recourse notes at an attractive cost of capital, with proceeds being utilized to fund both the Theravance Biopharma acquisition and continued share repurchases. Our financing strategy and the share repurchase program have focused on minimizing equity dilution to our shareholders. We completed our last public equity offering in January 2022 and have no current plans for additional equity issuances.”

Adjusted EBITDA is a non-GAAP financial measure. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. A reconciliation between GAAP reported and non-GAAP financial information for historical results is provided at the end of this earnings release.

Zymeworks 2026 Share Repurchase Program

In May 2026, the Board of Directors authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. As of September 28, 2026, the Company has utilized approximately $49.3 million of this current approved repurchase program to acquire 1,971,454 shares at an average price of $25.04 per share (exclusive of commission expense and estimated excise tax).

Since initiating its share repurchase program in August 2024, the Company has cumulatively utilized $211.6 million to reacquire 10,571,316 shares at an average price of $20.02 per share (exclusive of commission expense and estimated excise tax). As of September 14, 2026, the Company had approximately 71.2 million common shares outstanding.

Investor Call Details

Zymeworks will host a conference call today with investors and the general public at 8:30 am ET. Dial-in details and webcast link are available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations. A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable Zymeworks to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated benefits of the acquisition of Theravance Biopharma; the anticipated benefits of the financing in connection with the closing of the acquisition; anticipated milestones payments; Zymeworks’ ability to utilize Irish tax attributes; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; future growth of YUPELRI® sales and future royalty payments; sales and future royalty payments related to VIBATIV®; contingent milestone payments due to Theravance Biopharma from the sale of Theravance Biopharma’s TRELEGY ELLIPTA® royalty interests; the repayment of the non-recourse note issued to OMERS Life Sciences; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; the Company’s 2026 full year guidance and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks related to the financing in connection with the closing of the acquisition; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI®, TRELEGY and VIBATIV®; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period; TRELEGY may not achieve anticipated sales resulting in sales milestones not being met; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Explanation of Non-GAAP Financial Information

In addition to reporting financial information in accordance with U.S. generally accepted accounting principles (GAAP) in this press release, the Company has elected to present Adjusted EBITDA, a non-GAAP financial measure, on a forward-looking basis. Zymeworks believes Adjusted EBITDA provides useful information regarding the Company’s underlying operating performance and facilitates comparisons of operating results across periods. Adjusted EBITDA should be considered in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. Other companies may calculate Adjusted EBITDA differently or may use other measures to evaluate their performance. Investors and others are encouraged to review Zymeworks’ financial information in its entirety and not rely on a single financial measure.

Adjusted EBITDA is calculated as net income (loss), adjusted to exclude income tax expense or benefit, interest income and expense, depreciation and amortization, other non-operating income or expense, share-based compensation expense, and certain other items, including transaction-related costs, restructuring charges and severance costs. A reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable GAAP financial measure, is included in the tables at the end of this press release.

A reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP measures is not available without unreasonable effort due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Accordingly, in reliance on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K, we have not provided a reconciliation of forward-looking Adjusted EBITDA provided in this press release. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations, and the GAAP measures may be materially different than the non-GAAP measures.

ZYMEWORKS INC.
GAAP to Non-GAAP Reconciliation
Adjusted EBITDA
(unaudited)
($ in millions)

  Three Months Ended June 30, Six Months Ended June 30,
    2026     2025     2026     2025  
         
Net income (loss) $                  (45.0 ) $                 2.3   $                  (89.2 ) $                 (20.3 )
Adjustments:        
Income tax benefit / (expense)                   (0.3 )                   (0.2 )                   (2.5 )                   0.3  
Interest expense / (income), net                   3.3                     (3.4 )                   2.7                     (6.9 )
Depreciation and amortization                   1.1                     2.5                     2.3                     5.1  
Other non-operating (income) / expense, net                   (0.2 )                   0.6                     (0.3 )                   0.6  
Share-based compensation expense                   11.3                     5.9                     18.3                     12.3  
Transaction-related costs                   3.0                     —                     3.0                     —  
Restructuring and severance costs                   0.1                     0.7                     3.4                     1.2  
Adjusted EBITDA $                 (26.7 ) $                 8.4   $                 (62.3 ) $                 (7.7 )

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today released an updated mine plan for its Snow Lake operations in Manitoba, Canada. All amounts are in U.S. dollars, unless otherwise noted.

  • Snow Lake’s proven and probable reserve mine life extended by an additional two years to 2043, which together with the four-year extension announced in March 2026 represents a total of six years added to the reserve mine life.
  • Updated 2026-2030 five-year average annual gold production to 185,000 ounces from continued strong mill throughput rates at New Britannia and higher gold recoveries at Stall, representing a 37% increase in total gold production from an additional 250,000 ounces produced over the same five-year period in the 2021 technical reporti.
  • Total life-of-mine gold production increased by 60% to 2.8 million ounces from 1.8 million ounces in the 2021 technical reporti.
  • Updated 2026-2030 five-year average gold cash costsii to $821 per ounce and five-year average sustaining cash costsii to $1,379 per ounce, maintaining industry leading operating margins.
  • Snow Lake mineral reserve estimates increased to 27 million tonnes containing 2.0 million ounces of gold, representing a 38% increase in tonnage from the January 1, 2026 mineral reserve estimate.
  • Snow Lake mineral resource estimates increased to 21 million tonnes containing 1.5 million ounces of gold, representing a 26% increase in tonnage from the January 1, 2026 mineral resource estimate, despite significant resource-to-reserve conversion.
  • Life-of-mine plan based on reserve estimates and represents a conservative view based on Hudbay’s historical high resource-to-reserve conversion rate of 90%iii and ongoing exploration activities.
  • 1901 exploration and development activities are progressing well, and the project is on track to achieve full production in late 2027.
  • Stall hot tailings project is underway and is expected to be commissioned in early 2028, resulting in further increases in gold and silver recoveries.
  • Longer-term production profile enhancement and reserve mine life extensions expected from continued conversion of mineral resources at Lalor, exploration at 1901 to unlock gold potential, reprocessing of Anderson tailings in Snow Lake, and additional exploration at existing satellite deposits in pursuit of a new anchor deposit.
  • The Britannia Gold Project presents a new anchor deposit opportunity to meaningfully add gold production and significantly extend mine life well beyond current reserves.

“This enhanced Snow Lake mine plan unlocks roughly 60% more gold production over the mine life and maintains an average of 185,000 ounces over the next five years, demonstrating the incredible value that we have created through successful exploration and continuous improvement initiatives,” said Peter Kukielski, Hudbay’s Chief Executive Officer. “Transitioning this operation from a zinc-rich operation to a leading Canadian gold operation over the last five years has been transformative for Hudbay and we look forward to sustainable production in the decades ahead. The strong margins and steady gold production will ensure Snow Lake continues to be a meaningful free cash flow contributor and provide complementary gold exposure for Hudbay. This gold diversification becomes even more valuable as we continue to advance our attractive copper growth pipeline to deliver significant long-term value for our stakeholders.”

“I am very pleased with the Manitoba team’s execution of a focused exploration program and the advancement of many high-return, low-capital intensity growth initiatives in Snow Lake to deliver this robust mine plan,” said Robert Carter, Hudbay’s Chief Operating Officer. “We have delivered on the strategy of targeting more than 180,000 ounces of annual gold production and we are well-positioned to continue to deliver that profile well into the next decade. The Snow Lake Greenstone Belt continues to be a highly prospective region and provides significant upside potential. Future opportunities include unlocking additional reserves through continued conversion of the 1.5 million gold ounces in inferred resources, further extending the reserve mine life beyond 2043 and exploring for the next major anchor deposit in Snow Lake.”

Hudbay’s 100% owned Snow Lake operations in Manitoba include the Lalor gold-copper-zinc mine, the New Britannia gold mill, the Stall base metals concentrator, the 1901 zinc-gold deposit, several satellite deposits and the former producing New Britannia gold mine currently on care and maintenance (“the Britannia Gold Project”). The Lalor mine achieved commercial production in 2014 and reached a significant milestone in December 2024 with the recovery of its one millionth ounce of gold from the mine. In 2025, an exploration drift was successfully completed to reach the 1901 mineralized zone to conduct underground exploration activities and establish critical infrastructure ahead of full production, which is expected in late 2027.

Hudbay increased its Snow Lake land package by more than 250% in 2023 through the acquisition of Rockcliff Metals Corp. (“Rockcliff”), which included the addition of several known deposits within trucking distance of the Snow Lake processing infrastructure, including the Talbot copper-zinc-gold deposit and the Rail copper-gold deposit. Hudbay signed its first-ever exploration agreement with the Kiciwapa Cree Nation related to Rail in 2024, followed by an exploration agreement with the Mosakahiken Cree Nation related to Talbot in 2025. Hudbay advanced drilling campaigns to expand the resource base at the satellite properties and upgrade mineral resources to mineral reserves, resulting in the inclusion of the Talbot and Rail deposits as mineral reserves in the Snow Lake updated mine plan.

Recent near-mine exploration at Lalor and regional exploration at the satellite properties have extended mine life through increased mineral reserves, unlocked additional gold ounces and added mineral resources to support further long-term production growth.

Unlocking Additional Gold Ounces Through Increased Mineral Reserves and Extended Mine Life to 2043

Current mineral reserve estimates in Snow Lake as of September 1, 2026 total 27.0 million tonnes with approximately 2.0 million ounces of gold and a reserve mine life to 2043. This represents an increase in mineral reserves of 7.5 million tonnes, unlocking 124,000 ounces of additional gold, and further extends mine life by two additional years, in each case as compared to the prior mineral reserve estimates dated January 1, 2026. Together with the increase in mineral reserves and four year mine life extension announced early this year, the Company has added a total of 510,000 ounces of gold contained in reserves and six years of additional mine life in Snow Lake.

The increase in reserves and extension of mine life is due to reserve conversion at Lalor and 1901 and higher reserves at the WIM and 3 Zone satellite deposits, in addition to the first reserve estimate for the Talbot and Rail satellite deposits following the completion of infill and geotechnical drilling. Please refer to Figure 1 for a summary of the additions to mineral reserves. Hudbay expects to continue to achieve high-grade resource to reserve conversions and to further optimize the mine plan.

Further background on each of the deposits included in the Snow Lake reserve mine plan is below:

  • Lalor – A geophysical discovery by Hudbay in 2007; the development of Lalor was approved in 2012 at a time when Lalor had an initial mine life of 10 years. Successful exploration since inception has delineated an approximate 300% increase in gold reserves, replacing depletion, and after having been in operation for 12 years, Lalor continues to have a reserve mine life of 11 years today.
  • 1901 – The 1901 deposit was discovered in 2019, and in 2020 and 2021 Hudbay conducted infill drilling, metallurgical testing and a pre-feasibility study. Underground drilling continues from an exploration drift to de-risk the pathway to full production at the end of 2027 and delineate additional gold reserves. 1901 is expected to increase the total mining rate from the Lalor shaft to 5,000 tonnes per day.
  • 3 Zone – Acquired by Hudbay in 2015 as part of the acquisition of New Britannia, this gold-rich deposit is located three kilometres from the New Britannia mill and is expected to come into production later this decade to supplement gold ore feed from Lalor.
  • WIM – Acquired by Hudbay in 2018, this copper-gold deposit is located 15 kilometres from the New Britannia mill and is expected to come into production after 3 Zone and contribute gold ore feed to the New Britannia mill after Lalor is depleted.
  • Talbot – Consolidated 100% ownership of this copper-zinc-gold deposit through Hudbay’s acquisition of Rockcliff in 2023. A successful infill drilling program was completed during the second quarter of 2026 as well as geotechnical drilling required for pre-feasibility study activities, which upgraded 2.7 million tonnes of mineral resources to reserves with approximately 130,000 ounces of gold, 52,000 tonnes of copper and a 10 year mine life.
  • Rail – Also acquired as part of Hudbay’s acquisition of Rockcliff in 2023, Hudbay’s 2024 drill program yielded new intersections of high-grade copper-gold mineralization. These results and the interpretation of historical drilling results were used to update the geological model and assess its economic potential. Rail has 1.5 million tonnes of reserves at 1.96% copper and 0.50 grams per tonne gold and is expected to provide feed for the Stall mill and come into production as 1901 is depleted.

Current mineral reserves for Lalor, 1901 and other Snow Lake satellite deposits as of September 1, 2026 are summarized in the following table.

Snow Lake Mineral Reserve Estimates1,2,3,4,5,6 000 Tonnes Au Grade (g/t) Cu Grade (%) Zn Grade (%) Ag Grade (g/t)
Gold Zone Reserves 
Gold Zone Proven
Lalor   4,667 3.78 0.43 0.70 21.8
Subtotal   4,667 3.78 0.43 0.70 21.8
Gold Zone Probable
Lalor   5,901 3.20 0.87 0.27 14.6
1901   341 2.66 0.75 0.68 15.2
WIM   3,653 1.17 1.29 0.21 5.1
Subtotal   9,895 2.43 1.02 0.26 11.1
Total Proven and Probable – Gold   14,562 2.86 0.83 0.37 14.5
Base Metal Zone Reserves 
Base Metal Proven
Lalor   4,977 2.02 0.32 4.15 25.7
1901   970 1.54 0.29 7.61 23.9
Subtotal   5,947 1.94 0.32 4.71 25.4
Base Metal Probable
Lalor   822 1.39 0.38 3.97 23.0
1901   307 2.17 0.27 7.27 27.4
Talbot   2,710 1.46 1.92 1.14 26.5
Rail   1,510 0.53 1.96 0.55 5.6
Subtotal   5,349 1.23 1.60 1.76 20.1
Total Proven and Probable – Base Metal   11,296 1.60 0.92 3.32 22.9
Total Gold and Base Metal Reserves – Proven and Probable
Lalor   16,367 2.92 0.55 1.76 20.5
1901   1,618 1.89 0.38 6.08 22.8
Talbot   2,710 1.46 1.92 1.14 26.5
WIM   3,653 1.17 1.29 0.21 5.1
Rail   1,510 0.53 1.96 0.55 5.6
Gold and Base Metal Proven and Probable   25,857 2.31 0.87 1.67 18.2
Britannia Gold Project – 3 Zone Probable   1,153 2.81 – – –
Total Proven and Probable – All Deposits   27,010 2.33 – – –

1 Totals may not add up correctly due to rounding.
2 The economic viability of the mineral reserve estimates was confirmed using metal prices of $1.25 per pound of zinc, $3,600 per ounce of gold, $5.00 per pound of copper, and $40.00 per ounce of silver with an exchange rate of 1.33 C$/US$. Lalor and 1901 mineral reserves were estimated using a minimum NSR cut-off for Stall mill ore material of C$160 longhaul and C$199 post pillar and a minimum NSR cut-off for New Britannia ore material of C$184 for longhaul and C$223 for post pillar.
3 3Zone, Talbot and Rail mineral reserves identified at an NSR cut-off value of C$150 per tonne. The NSR considers the metallurgical recoveries via processing at the Stall mill. WIM mineral reserves identified at an NSR cut-off value of C$125 per tonne.
4 WIM mineral reserves are estimated assuming processing recoveries of 98% for copper, 88% for gold, and 70% for silver based on processing through New Britannia’s flotation and tails leach circuits.
5 3 Zone mineral reserves are estimated assuming processing recoveries of 85% for gold based on processing through New Britannia’s leach circuit.
6 Mineral reserves include internal and external dilution and mining recovery.

Snow Lake Updated Mine Plan Maintains 185,000 Ounce Annual Gold Production Profile to 2030 and Demonstrates a 60% Increasei in Life-of-Mine Gold Production

Hudbay’s updated Snow Lake mine plan based solely on mineral reserve estimates reflects a 37% increase in gold production over the next five yearsi and a 60% increase in total gold production over the life-of-mine compared to the 2021 technical reporti, as outlined in Figure 2. Three-year average annual production from 2026 to 2028 of approximately 190,000 ounces of gold and 11,500 tonnes of copper is consistent with previously issued three-year production guidance. The updated Snow Lake mine plan maintains average production of 185,000 ounces of gold over the next five yearsi reflecting several optimization initiatives including higher mill throughput at New Britannia and higher gold recoveries at the Stall mill to better utilize the combined 6,300 tonnes per day of processing capacity, as shown in Figure 3 and further described below.

  • Higher Mining Rate – The updated Snow Lake mine plan reflects a mining ramp up to approximately 2.0 million tonnes per year and maintaining this profile over the next decade. The mine plan reflects Lalor operating at 4,000 to 4,500 tonnes per day, supplemented by contributions from the 1901 deposit and several additional satellites to supplement Lalor mill feed and increase total ore mined to approximately 5,000 tonnes per day.
  • Increased New Britannia Mill Throughput – The New Britannia mill has a nameplate design of 1,500 tonnes per day and a permitted capacity of 2,500 tonnes per day. Snow Lake’s mine plan has been optimized for higher mill throughput rates at New Britannia maximizing gold production and cash flows. The New Britannia mill currently operates at more than 2,000 tonnes per day, continuing to exceed expectations, and the updated mine plan reflects New Britannia ramping up to 2,300 tonnes per day starting in 2027.
  • Better Utilization of Available Processing Capacity at Stall – The Stall mill has a nameplate capacity of 3,800 tonnes per day but is currently operating at approximately 2,300 tonnes per day. The updated Snow Lake mine plan takes advantage of the spare capacity at Stall by adding 1901 zinc-rich reserves to the mine plan and maintains future optionality for other regional deposits. The updated mine plan reflects Stall throughput ramping up to 3,000 tonnes per day by 2030.
  • Stall Hot Tails Leaching Project – Stall has a history of continuous improvement projects increasing copper and precious metal recoveries, including the recovery improvement program that was completed in 2023 and increased gold recoveries from 58% in 2022 to more than 70% today. The Stall Hot Tails Leaching project continues this trend and aims to recover additional gold and silver through expansion of cyanide leaching and carbon infrastructure at New Britannia to accommodate material from Stall. Commissioning of this project is expected in early 2028 and it is anticipated to increase combined mill gold and silver recoveries as shown in Figure 4.
Snow Lake Production Profile1 2026E 2027E 2028E 2029E 2030E 2031-2035 (5Yr avg) 2036-2040 (5Yr avg)4 LOM Total1
Ore Mined
Lalor and1901 000 tonnes 1,512 1,702 1,742 1,749 1,748 1,570 1,318 18,938
Regional deposits 000 tonnes – – – – 247 544 748 9,025
Total Ore Mined 000 tonnes 1,512 1,702 1,742 1,749 1,996 2,114 1,275 27,963
Gold grade g/t Au 4.67 3.97 3.59 3.53 3.03 2.07 1.58 2.41
Copper grade % Cu 0.78 0.69 0.77 0.85 0.67 0.62 1.03 0.83
Zinc grade % Zn 1.86 2.06 1.48 1.91 1.42 1.90 1.36 1.62
Silver grade g/t Ag 26.7 22.6 20.9 22.4 17.0 16.6 16.1 17.7
Ore Milled
New Britannia 000 tonnes 758 872 874 874 879 871 872 15,301
Stall 000 tonnes 771 830 868 875 1,117 1,243 1,0085 12,679
Total Ore Milled 000 tonnes 1,529 1,702 1,742 1,749 1,996 2,114 1,275 27,980
Combined Recovery – New Britannia and Stall
Gold recovery % 88.3 85.5 91.2 91.1 90.5 89.4 86.4 88.9
Copper recovery % 90.1 89.8 91.4 91.9 91.8 86.5 89.6 89.7
Zinc recovery2 % 82.3 87.6 84.0 86.9 83.8 86.1 86.25 85.9
Silver recovery % 74.6 73.4 79.5 79.1 77.1 76.5 81.7 77.6
Production
Gold   000 ounces 201 186 183 181 176 126 57 1,931
Copper   000 tonnes 11 11 12 14 12 11 12 209
Zinc   000 tonnes 18 28 19 26 22 31 11 325
Silver   000 ounces 967 909 931 998 840 865 522 12,380
Total AuEq 3 000 ounces 262 250 247 255 242 186 90 2,716
Total CuEq3 000 tonnes 87 82 82 82 75 61 29 883

1 LOM totals reflect the mine plan for full year 2026 to 2043 and may be slightly different than the mineral reserve estimates which are as of September 1, 2026. Totals may not add up correctly due to rounding.
2 Zinc recoveries reflect zinc circuit at Stall mill only.
3 Copper and gold equivalent production assumes the following commodity prices: $6.09 per pound of copper for 2026, $5.80 per pound of copper for 2027, $5.50 per pound of copper for 2028 to 2030 and $5.00 per pound of copper long-term; $4,472 per ounce of gold for 2026, $4,200 per ounce of gold for 2027, $4,000 per ounce of gold for 2028, $3,900 per ounce of gold for 2029, $3,750 per ounce of gold for 2030 and $3,600 per ounce of gold long-term; $70 per ounce of silver for 2026, $57.50 per ounce of silver for 2027, $55.00 per ounce of silver for 2028, $50 per ounce of silver for 2029, $45 per ounce of silver for 2030 and long-term; $1.59 per pound of zinc for 2026, $1.40 per pound of zinc for 2027, $1.35 per pound of zinc for 2028, $1.30 per pound of zinc for 2029 and 2030, and $1.25 per pound of zinc long-term.
4 Individual mine and mill averages reflect their respective operating periods during 2036–2040 and therefore do not sum to the five-year total averages.
5 Stall mill ends processing in 2037 – amounts represent ore milled and recoveries in 2036-2037.

Executing Low-Capital Intensity Brownfield Growth Projects to Deliver Strong Returns

The Snow Lake capital expenditures profile reflects several growth initiatives, including the completion of the development of the 1901 deposit, the implementation of the Stall Hot Tails Leaching project and the optionality maintained from developing the regional satellite deposits. Sustaining capital expenditures reflect underground capitalized development activities, equipment purchases and tailings dam capital required to maintain operations.

Hudbay expects to continue to significantly enhance this conservative mine plan based solely on mineral reserve estimates by prioritizing high grade resource to reserve conversions from the Lalor and 1901 deposits with lower associated capital expenditures.

Combined mining, milling and G&A unit operating costs on a tonne milled basis remains relatively unchanged over the mine life as the increase in mill throughput offsets higher mining costs as mining activities go deeper and haulage distances increase. Over the next five years, average gold cash costsii of $821 per ounce and average sustaining cash costsii of $1,379 per ounce benefit from continued strong gold production and by-product credits. Without any further exploration success, cash costs are expected to increase in the 2030s but maintain highly attractive margins when compared to other gold operations and long-term gold price estimates.

Snow Lake Capital and Cost Profile 2026E 2027E 2028E 2029E 2030E 2031-2035 (5Yr avg) 2036-2040 (5Yr avg) LOM Total1
Capital Expenditures
Sustaining Capital
Lalor and 1901 $ millions 57 75 62 68 53 13 – 379
Plant and other $ millions 47 7 18 15 3 5 4 143
Regional deposits $ millions – – – – 14 17 27 235
Growth Capital
Lalor and 1901 $ millions 14 13 4 – – – – 31
Plant and other $ millions 10 48 – 19 – – – 77
Regional deposits $ millions – 4 32 28 4 83 – 480
Unit Costs and Cash Costs on a Gold Basis Capital
Unit operating costs C$/tonne processed 262 254 261 263 256 235 221 240
Cash cost2 $/ounce 485 762 912 829 1,163 1,518 1,175 1,110
Sustaining cash cost2 $/ounce 1,086 1,295 1,473 1,402 1,682 1,813 1,742 1,560

1 LOM totals reflect the mine plan for full year 2026 to 2043 and may be slightly different than the mineral reserve estimates which are as of September 1, 2026. For unit operating costs and cash costs, LOM represents the average annual cost. Totals may not add up correctly due to rounding.
2 Cash costs and sustaining cash costs on a gold basis assumes the following commodity prices: $6.09 per pound of copper for 2026, $5.80 per pound of copper for 2027, $5.50 per pound of copper for 2028 to 2030 and $5.00 per pound of copper long-term; $4,472 per ounce of gold for 2026, $4,200 per ounce of gold for 2027, $4,000 per ounce of gold for 2028, $3,900 per ounce of gold for 2029, $3,750 per ounce of gold for 2030 and $3,600 per ounce of gold long-term; $70 per ounce of silver for 2026, $57.50 per ounce of silver for 2027, $55.00 per ounce of silver for 2028, $50 per ounce of silver for 2029, $45 per ounce of silver for 2030 and long-term; $1.59 per pound of zinc for 2026, $1.40 per pound of zinc for 2027, $1.35 per pound of zinc for 2028, $1.30 per pound of zinc for 2029 and 2030, and $1.25 per pound of zinc long-term.

Mineral Resources Increase by 26% and Provide Significant Opportunity to Further Increase Gold Production and Extend Mine Life

Total mineral resources (exclusive of mineral reserves) have increased by 4.2 million tonnes in 2026, despite significant resource-to-reserve conversion. This was through additional resource expansion at Lalor and 1901, in addition to successful exploration at the regional satellite deposits to delineate additional resources as well as the inclusion of the Britannia Gold Project, as shown in Figure 1 and detailed below.

Snow Lake Mineral Resource Estimates1,2,3,4,5,6 000 Tonnes Au Grade (g/t) Cu Grade (%) Zn Grade (%) Ag Grade (g/t)
Gold Zone Resources – Inferred    
Lalor   1,540 3.38 1.90 0.19 12.4
1901   3,300 2.87 0.94 0.49 10.2
WIM   1,120 1.44 0.70 0.25 3.4
Total Gold Zone Resources – Inferred   5,960 2.73 1.14 0.36 9.5
Base Metal Resources – Inferred
Lalor   140 1.94 0.28 5.14 32.5
1901   780 2.19 0.23 6.55 41.6
Talbot   880 2.23 1.52 1.17 29.6
Rail   740 1.03 3.29 0.55 8.9
Watts   3,150 1.00 2.34 2.58 31.0
Pen II   600 0.30 0.46 9.09 6.8
Total Base Metal Resource – Inferred   6,290 1.28 1.85 3.31 27.2
Total Gold and Base Metal Resources – Inferred
Lalor   1,680 3.26 1.77 0.60 14.1
1901   4,080 2.74 0.80 1.65 16.2
Talbot   880 2.23 1.52 1.17 29.6
WIM   1,120 1.44 0.70 0.25 3.4
Rail   740 1.03 3.29 0.55 8.9
Watts   3,150 1.00 2.34 2.58 31.0
Pen II   600 0.30 0.46 9.09 6.8
Total Gold and Base Metal Resources – Inferred   12,250 1.98 1.51 1.88 18.6
Britannia Gold Project – Inferred
Upper Britannia   3,180 2.83 – – –
Lower Britannia   2,520 3.44 – – –
Boundary   1,420 2.23 – – –
Birch   1,140 2.51 – – –
Total Britannia Gold Project – Inferred   8,260 2.87 – – –

1 Totals may not add up correctly due to rounding.
2 Mineral resources listed in the chart above are exclusive of mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability.
3 Mineral resources in the above table do not include mining dilution or recovery factors.
4 Base metal mineral resources are estimated based on the assumption that they would be processed at the Stall concentrator while gold mineral resources are estimated based on the assumption that they would be processed at the New Britannia concentrator.
5 Metal prices of $1.25 per pound of zinc, $3,600 per ounce gold, $5.00 per pound copper, and $40.00 per ounce silver with an exchange rate of 1.33 C$/US$ were used to estimate mineral resources.
6 Mineral resources are estimated using a minimum NSR cut-off of C$160 per tonne for Lalor and 1901, C$125 per tonne for WIM and C$150 per tonne for all other deposits.

Significant Resource Expansion Potential Through the Britannia Gold Project

In addition to the 12.3 million tonnes of inferred mineral resources in the regional satellite deposits, Hudbay has significantly expanded the inferred resources at the Britannia Gold Project to 8.3 million tonnes:

  • Britannia Gold Project was a Significant Historic Gold Producer – Acquired by Hudbay in 2015 with the acquisition of the New Britannia gold mill, the New Britannia mine is a former producing gold mine that produced approximately 600,000 ounces between 1949 and 1958 and an additional 800,000 ounces between 1995 and 2005. The Britannia Gold Project includes the New Britannia mine and nearby gold zones.
  • Significant Mineral Resources Remain accessible at New Britannia – Hudbay is advancing plans for potential future development and rehabilitation of the existing mining infrastructure at the New Britannia mine to unlock significant incremental gold production in Snow Lake.
  • Mineralized Corridor Spans Five Major Deposits – All of the deposits remain open at depth with high-grade ore shoots tracking in a predictable plunge direction, as shown in Figure 5.
  • Surface Exploration Underway – Large, untested gaps between the known deposits and along the strike of the major controlling thrust fault to the east present immediate potential for new discoveries and resource expansion. Initial target testing is underway from surface and future underground exploration plans can be accelerated through existing underground infrastructure.

Snow Lake Operational and Exploration Upside Potential

Hudbay continues to advance many brownfield expansion and exploration opportunities to further optimize the mine plan to maintain current annual gold production levels beyond 2030, extend mine life beyond 2043 and explore for new anchor deposits to provide significant gold production growth beyond the 180,000-ounce annual target. This includes executing an extensive exploration program in Snow Lake through geophysical surveying and multi-phased drilling campaigns on the highly prospective land package, as referenced in Figure 6.

1)   Conversion of Large Inferred Resources to Further Increase Production and Extend Mine Life – Continued infill drilling of existing resource base at Lalor and known satellites will continue to support mine plan optimization.

    • Potential to convert the 1.5 million ounces of gold in inferred resources to reserves through infill drilling.
    • Hudbay has historically converted approximately 90% of inferred resources to reserves at the Lalor deposit over the past five yearsiii.

2)   Additional Mill Optimization Initiatives – Evaluating additional mill throughput enhancements to further increase annual production levels.

    • New Britannia has steadily increased its milling rate since refurbishment was completed in 2021, and the current plan assumes increasing New Britannia’s milling rate to 2,300 tonnes per day.
    • Hudbay will evaluate opportunities to further increase mill throughput at New Britannia to fully utilize its full permitted capacity of 2,500 tonnes per day.

3)   Reprocessing of Snow Lake Tailings to Unlock Additional Gold Ounces – Advance engineering work to evaluate the viability of reprocessing tailings from the Anderson Tailings Impoundment Area (“ATIA”) in Snow Lake.

    • Advance engineering work to evaluate the potential of reprocessing tailings from the Anderson Tailings Impoundment Area (“ATIA”) in Snow Lake.
    • Hudbay has identified 20 to 30 million tonnes of material at approximately 0.8 to 1.0 gram per tonne gold at ATIA that could potentially be reprocessed.
    • Drilling, metallurgical studies and dredging trials are planned in 2027-2029 to confirm potential.

4)   Extension of the Current Anchor Deposit – Maximize value from existing infrastructure through mine life extension at the highest margin deposits, while extending the window of opportunity to discover a new anchor deposit.

    • Lalor and 1901 provide high NSR value per tonne and remain open down plunge.
    • Mine life extensions at the current anchor will further increase cash flows and defer growth capital associated with the development of satellite deposits.

5)   Discovery of a New Anchor Deposit – Meaningfully add to current production levels and significantly extend mine life through the discovery of the next major anchor deposit in Snow Lake.

    • The Britannia Gold Project provides the opportunity to re-develop an underexplored, past-producing deposit with the potential to become a new anchor in the Snow Lake camp, as shown in Figure 5 and discussed above.
    • Regional exploration on the large and highly prospective land package, including exploration for both volcanogenic massive sulphide (VMS) and orogenic gold deposits.

Snow Lake Site Tour

Hudbay is hosting a site visit by analysts and investors to its Snow Lake operations in Manitoba on Thursday, October 1, 2026. A copy of the site visit presentation, which will contain operational and other updates, will be available on Hudbay’s website at www.hudbay.com.

Qualified Person and NI 43-101

Hudbay’s mineral resource estimates in this news release are exclusive of mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

The technical and scientific information in this news release has been approved by Marc-Andre Brulotte, P. Geo., Executive Director, Global Mineral Resource Evaluation. Mr. Brulotte is a qualified person pursuant to National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

A copy of the NI 43-101 technical report will be made available on Hudbay’s SEDAR+ profile at www.sedarplus.ca and on Hudbay’s EDGAR profile at www.sec.gov within the next 45 days. This technical report will support the applicable disclosure in this news release and will be the current technical report in respect of the Snow Lake operations and shall supersede and replace all prior technical reports relating to the Snow Lake operations.

Forward-Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities legislation. Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information.

Forward-looking information includes, but is not limited to, statements with respect to the Company’s expectations regarding the production, cost profile and development timelines of its Snow Lake operations, including with respect to its anticipated mine life, the potential to extend the mine life, the potential to convert inferred mineral resources into mineral reserves based on historical conversion rates, opportunities to and further optimize the mine plan, the potential of the Stall Hot Tails Leaching project to improve metal recoveries, the potential of the Britannia Gold Project, including its potential to become a new anchor deposit, the potential to reprocess tailings from the ATIA, as well as expectations regarding metals prices, operating and capital costs and other assumptions. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information.

The material factors or assumptions that Hudbay has identified and were applied in drawing conclusions or making forecasts or projections set out in the forward-looking information include, but are not limited to:

  • the ability to achieve production, cost and capital expenditure forecasts;
  • the ability to obtain the necessary permits and social license to develop the satellite deposits that have been included in the Snow Lake mine plan;
  • the ability to execute on the Company’s exploration plans and to advance related drill plans;
  • the success of mining, processing, exploration and development activities;
  • the scheduled maintenance and availability of the Company’s processing facilities;
  • the accuracy of geological, mining and metallurgical estimates;
  • anticipated metals prices and the costs of production;
  • the supply and demand for metals the Company produces;
  • the supply and availability of all forms of energy and fuels at reasonable prices;
  • no significant unanticipated operational or technical difficulties;
  • the availability of additional financing, if needed;
  • the ability to complete project targets on time and on budget and other events that may affect the Company’s ability to develop its projects;
  • the timing and receipt of various regulatory and governmental approvals;
  • the availability of personnel for the Company’s exploration, development and operational projects and ongoing employee relations;
  • maintaining good relations with the employees at the Company’s operations;
  • maintaining good relations with the labour unions that represent certain of the Company’s employees in Manitoba;
  • maintaining good relations with the communities in which the Company operates, including neighbouring Indigenous communities and local governments;
  • no significant unanticipated challenges with stakeholders at the Company’s various projects;
  • no significant unanticipated events or changes relating to regulatory, environmental, health and safety matters;
  • no contests over title to the Company’s properties, including as a result of rights or claimed rights of Indigenous people;
  • no significant unanticipated litigation;
  • certain tax matters, including, but not limited to current tax laws and regulations, changes in taxation policies and the refund of certain value added taxes from the Canadian government; and
  • no significant and continuing adverse changes in general economic conditions or conditions in the financial markets (including commodity prices and foreign exchange rates).

The risks, uncertainties, contingencies and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking information may include, but are not limited to, risks generally associated with the mining industry and the current geopolitical environment, including fluctuations in commodity prices, the potential implementation or expansion of tariffs, currency and interest rate fluctuations, energy and consumable prices, supply chain constraints and general cost escalation in the current inflationary environment, uncertainties related to the development and operation of the Company’s projects, risks associated with the development of new projects, risks related to the Snow Lake mine plan, including the ability to sequence the permitting and development of multiple satellite deposits, risks related to historical agreements in respect of the New Britannia mine, risks related to reclamation and closure liabilities, dependence on key personnel and employee and union relations, risks related to political or social instability, unrest or change, risks in respect of Indigenous and community relations, rights and title claims, operational risks and hazards, including the cost of maintaining and upgrading the Company’s tailings management facilities and any unanticipated environmental, industrial and geological events and developments and the inability to insure against all risks, failure of plant, equipment, processes, transportation and other infrastructure to operate as anticipated, compliance with government and environmental regulations, including permitting requirements and anti-bribery legislation, depletion of the Company’s reserves, volatile financial markets and interest rates that may affect the Company’s ability to obtain additional financing on acceptable terms, the failure to obtain or maintain required permits or approvals from government authorities on a timely basis, uncertainties related to the geology, continuity, grade and estimates of mineral reserves and resources and the potential for variations in grade and recovery rates, uncertain costs of reclamation activities, the Company’s liquidity risks and its ability to access capital on acceptable terms, tax refunds, hedging transactions, cybersecurity risks and risks related to the reliability and security of the Company’s information technology and operational technology systems, including risks arising from cyber attacks, ransomware, phishing and other malware, risks associated with the use of artificial intelligence technologies, operational disruptions arising from environmental events such as wildfires or other forms of extreme weather, as well as the other risks discussed under the heading “Risk Factors” in Hudbay’s most recent Annual Information Form for the year ended December 31, 2025 and under the heading “Financial Risk Management” in the Company’s most recent annual management’s discussion and analysis for the year ended December 31, 2025 which are available on the Company’s SEDAR+ profile at www.sedarplus.ca and the Company’s EDGAR profile at www.sec.gov.

Should one or more risk, uncertainty, contingency or other factor materialize or should any factor or assumption prove incorrect, actual results could vary materially from those expressed or implied in the forward-looking information. Accordingly, you should not place undue reliance on forward-looking information. Hudbay does not assume any obligation to update or revise any forward-looking information after the date of this news release or to explain any material difference between subsequent actual events and any forward-looking information, except as required by applicable law.

About Hudbay

Hudbay (TSX, NYSE: HBM) is a copper-focused critical minerals mining company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining jurisdictions of Canada, Peru and the United States.

Hudbay’s operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada) and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the Company, which is complemented by meaningful gold production and by-product zinc, silver and molybdenum. Hudbay’s growth pipeline includes the Copper World project in Arizona (United States), the Cactus project in Arizona (United States), the Mason project in Nevada (United States), the Llaguen project in La Libertad (Peru) and several expansion and exploration opportunities near its existing operations.

The value Hudbay creates and the impact it has is embodied in its purpose statement: “We care about our people, our communities and our planet. Hudbay provides the metals the world needs. We work sustainably, transform lives and create better futures for communities.” Hudbay’s mission is to create sustainable value and strong returns by leveraging its core strengths in community relations, focused exploration, mine development and efficient operations.

For further information, please contact:

Candace Brûlé
Senior Vice President, Capital Markets & Corporate Affairs
(416) 362-8181
investor.relations@hudbay.com

____________________
i Average gold production over the 2026 to 2030 five-year period. Total life-of-mine (“LOM”) gold production compares total LOM gold production in the 2021 technical report to total LOM gold production in the 2026 updated mine plan plus actual production since 2021.
ii Cash costs and sustaining cash costs are non-GAAP financial performance measures with no standardized definition under IFRS. For detailed reconciliations and further information on why Hudbay believes cash costs and sustaining cash costs are useful performance indicators, please refer to the Company’s most recent management’s discussion and analysis for the period ended June 30, 2026 under the heading “Non-GAAP Financial Performance Measures”.
iii Resource-to-reserve conversion rate based on the historical conversion at the Lalor deposit from 2022 to 2026.

Figure 1: Continuously Expanding Reserves in Snow Lake

Hudbay has continuously extended the mine life of Snow Lake through reserve expansion and upgrading of resources at satellite deposits, which has more than offset mining depletion since the prior technical report published in 2021.

Figure 1

Figure 2: Unlocking Additional Gold Production and Extending Mine Life Through Successful Exploration
Snow Lake maintains a robust gold production profile for the next 10 years, averaging 185,000 ounces of gold per year from 2026 to 2030 and 126,000 ounces of gold per year from 2031 to 2035, largely supported by Lalor, followed by production from the remaining satellites to 2043. The previous technical report published in 2021 reflected a ten year mine life for Lalor to 2030 with satellite deposits in production from 2031 to 2037.

Figure 2

Figure 3: Snow Lake Production Profile by Ore Body

Lalor provides a majority of the ore for the next 11 years with 1901, 3 Zone, Talbot, Rail and WIM providing the additional ore feed and supporting a combined 18 year mine life based on reserves. This profile is expected to be further enhanced with additional exploration to convert resources to reserves and extend mine life beyond 2043.

Figure 3

Figure 3

Figure 4: Optimizing Processing Infrastructure and Increasing Total Gold Recoveries

The updated Snow Lake mine plan reflects optimized ore feed to New Britannia and Stall mills, higher mill throughput at New Britannia and higher gold recoveries at Stall.

Figure 4

Figure 5: Britannia Gold Project

Hudbay has the opportunity to re-develop a past-producing gold complex into a potential new anchor deposit with the Britannia Gold Project around the New Britannia mill. Multiple targets are being developed down-plunge and along strike from the known mineralization.

Figure 5

Figure 6: Regional Snow Lake Satellite Deposits

Hudbay increased its land package in Snow Lake by 250% in 2023, adding several regional satellite properties located within trucking distance of the Company’s processing infrastructure. The Company then launched a significant multi-year geophysics program that included surface electromagnetic surveys using modern technology to target depths up to 1,000 metres. These efforts will continue in 2026 and 2027 with the largest geophysics program in Hudbay’s history.

Figure 6

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/5a657ae8-a7d8-450a-9455-41510e3589b6
https://www.globenewswire.com/NewsRoom/AttachmentNg/0f72699a-1978-493f-9a31-05384e0a7b99
https://www.globenewswire.com/NewsRoom/AttachmentNg/f6b9d735-c166-4508-8225-a83d5b65f8c9
https://www.globenewswire.com/NewsRoom/AttachmentNg/d46974a3-5787-453e-89ec-7ef27f3c8032
https://www.globenewswire.com/NewsRoom/AttachmentNg/275b3086-4063-48a7-8502-7d3d6b88efa9
https://www.globenewswire.com/NewsRoom/AttachmentNg/417acfc4-0206-4ab9-9234-4223c7dd169f
https://www.globenewswire.com/NewsRoom/AttachmentNg/e7253de4-9b89-4fcc-a22c-59a6c04bf215

Announced Transactions Expected to Complete Pivot to Pure-Play SHOP and Reduce Net Debt to Further Adjusted EBITDA to 0x Based on Q2 2026 Financials 
6.9% Nominal and 6.5% Economic Cap Rates on Anticipated OMF Portfolio Sale Facilitate Accretive Execution of Growing SHOP Acquisition Pipeline 

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHP) (the “Company”) announced today the following business updates:

OMF Dispositions under Definitive Agreement and Letter of Intent

The Company entered into a definitive purchase and sale agreement to sell 40 outpatient medical facilities (“OMFs”) for approximately $531 million. Based on trailing twelve-month in-place cash net operating income (“NOI”), the sale price represents a nominal cap rate of 6.9%. After adjusting for recurring capital expenditures over the same period, as well as capital expenditure and other customary adjustments at closing, the Company expects the sale to result in an economic cap rate of 6.5%.

Having recently retired all secured debt related to this portfolio, the Company expects estimated cash proceeds of $511 million before transaction expenses and property operating prorations but inclusive of capital expenditure and other customary adjustments. The Company expects to utilize these cash proceeds to repay the balance on the Company’s revolving credit facility, fund senior housing operating portfolio (“SHOP”) acquisitions and for general corporate purposes. The sale is expected to close in the fourth quarter of 2026, subject to customary closing conditions.

Based on announced disposition and capital markets transactions as well as closed SHOP acquisitions, the Company expects Net Debt to Further Adjusted EBITDA to approximate 0x (based on second quarter 2026 financials). In this scenario, the Company would hold cash and cash equivalents approximately equal to total debt comprised primarily of $300 million of outstanding unsecured term loans.

The Company also signed a non-binding letter of intent for its final four OMFs for gross proceeds of $11 million.

Inclusive of these transactions and the previously announced sale of 86 OMFs for approximately $528 million (including the sale of 30 OMFs closed on September 10, 2026), the Company expects to fully exit the OMF segment.

SHOP Pipeline

The Company currently has signed purchase and sale agreements or non-binding letters of intent for approximately $244 million of SHOP acquisitions, comprised of 724 primarily assisted living and memory care units, with estimated weighted average year-one and year-three cap rates of approximately 7.2% and 8.4%, respectively. Closing of these acquisitions is subject to continued purchaser due diligence, closing conditions and regulatory approvals as specified in the applicable agreements.

Michael Anderson, Chief Executive Officer and President, commented, “These expected transactions complete our strategic evolution into a pure-play SHOP platform with meaningful internal growth and a conservative, largely unencumbered balance sheet. Moreover, we believe the economics of our exit from the OMF segment will immediately provide additional capacity for the accretive execution of our robust and growing pipeline of high-acuity SHOP acquisition opportunities. As the population of older adults continues to expand and the need for specialized senior housing and care increases, we believe our focused strategy positions us well to capture the growth from this long-term demographic trend.”

About National Healthcare Properties

National Healthcare Properties, Inc. (Nasdaq: NHP) is a self-managed real estate investment trust focused on acquiring, owning and investing in a diversified portfolio of healthcare real estate, with an emphasis on providing senior housing to serve a growing elderly population in the United States. Additional information about the Company can be found on its website at nhpreit.com.

Investor & Media Contact

Email: ir@nhpreit.com

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “predict,” “project,” “potential,” “continue” or the negatives of these terms or variations of them or similar expressions. Examples of forward-looking statements include statements regarding the timing, closing and proposed use of proceeds of OMF disposition, the expected benefits of the OMF disposition and SHOP acquisitions, future acquisition and disposition opportunities and other statements regarding the Company’s future strategy. Risks and uncertainties, the occurrence of which could adversely affect the Company’s business and cause actual results to differ materially from those expressed or implied in the forward-looking statements, include, but are not limited to, the following: changes in economic cycles generally and in the real estate and healthcare markets specifically; the success of the Company’s growth strategy, including its ability to successfully identify, complete and integrate new acquisitions; the Company’s ability to complete acquisitions or dispositions on the terms and timing the Company expects, or at all; changes to inflation and interest rates; competition in the real estate and healthcare markets; the Company’s ability to retain certain key personnel; legislative and regulatory changes in the healthcare and real estate industries; reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid; discovery of previously undetected environmentally hazardous conditions; the Company’s ability to pay down, refinance, restructure or extend its indebtedness as it becomes due; system failures, cyber incidents or deficiencies in the Company’s cybersecurity systems; the availability of capital on favorable terms, or at all; the Company’s ability to remain qualified as a real estate investment trust for U.S. federal income tax purposes; and other risks and uncertainties described in the section titled Risk Factors of the Company’s most recent Annual Report on Form 10-K and all other filings with the Securities and Exchange Commission. Cash NOI is defined as NOI excluding non-cash items such as straight-line rent adjustments and amortization of above and below market lease and lease intangibles that are included in GAAP revenue from tenants and property operating and maintenance. Cap rates for the Company’s acquisition pipeline included in this press release are calculated by dividing the underwritten cash NOI that the Company aims to achieve (some of which are based on preliminary information provided by sellers and certain assumptions applied by the Company) by the total aggregate purchase price, not including certain initial acquisition capital expenditures. The actual stabilized cash NOI yields from the Company’s pipeline may not be consistent with the targeted stabilized cash NOI yield range. Finally, the Company assumes no obligation to update or revise any forward-looking statements or to update the reasons why actual results could differ from those projected in any forward-looking statements. You can find the definitions of GAAP financial measures referenced in this press release and their reconciliations to the most directly comparable GAAP financial measures in our most recent annual and quarterly supplemental materials as made available on our website at http://investors.nhpreit.com under the heading “Quarterly Results.”

Includes 28.5 Metres Averaging 2.31% Cu and 11.8 g/t Ag

South-Western Extension provides additional high-grade intercept of 86 metres averaging 1.36% Cu

MONTREAL, Sept. 28, 2026 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce additional new analytical results from the 2026 drill program at the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec.

New results are presented below (see Table 1), including 28 mineralized intercepts from 12 drill holes. Reported “infill” intercepts are located within the 2026 MRE model (see April 14, 2026 news release), focused on upgrading Inferred Mineral Resources to Measured or Indicated categories, as applicable. “Expansion” intercepts are located outside the 2026 MRE model and comprise either i) in-pit expansion, which offers potential to convert in-pit waste into additional resources within the 2026 MRE Whittle pit; or ii) out-of-pit expansion, consisting of mineralization located outside the 2026 MRE Whittle pit, which may potentially lead to the definition of new resources. Some of the reported intercepts may have contiguous shallower infill as well as deeper in-pit expansion (noted as “Both”). Maps showing hole locations are available at www.osiskometals.com.

Osisko Metals Chief Executive Officer Robert Wares commented: “Another series of excellent results from the north slope of Needle Mountain, including particularly two high-grade intercepts in holes 30-1236 and 30-1243, both located 500 to 600 metres west of the 2026 MRE model. The mineralized system continues to show grade improvement in the area around Needle Mountain and we are confident that these mineralized zones will be included in a westerly pit expansion in the next resource update.”

20260928 Osisko Metals news release Figure 1/plan view

20260928 Osisko Metals news release Figure 2/long section

Highlights

  • 211.5 metres averaging 0.59% Cu (out-of-pit expansion) in DDH 30-1243, including 28.5 metres averaging 2.31% Cu and 11.8 g/t Ag
  • 86.5 metres averaging 1.36% (out-of-pit expansion) in DDH 30-1236, including 18.0 metres averaging 4.53% Cu and 23.3 g/t Ag
  • 63.8 metres averaging 0.98% Cu (out-of-pit expansion) in DDH 30-1239, including 16.1 metres averaging 2.54% Cu and 8.98 g/t Ag
  • 81.2 metres averaging 0.50% Cu (in-pit expansion) in DDH 30-1237, including 5.0 metres averaging 2.29% Cu and 16.4 g/t Ag
  • 201.0 metres averaging 0.33% Cu (infill) in DDH 30-1245
  • 54.0 metres averaging 0.44% Cu (in-pit expansion) in DDH 30-1241

Table 1: Infill and Expansion Drilling Results

DDH No. From (m) To (m) Length (m) Cu % Ag g/t Mo % CuEq* % Type**
30-1236 42.5 73.0 30.5 0.39 2.08 <0.005 0.39 Expansion 2
and 93.6 112.0 18.4 0.46 3.11 <0.005 0.47 Expansion 2
and 145.5 167.5 22.0 0.32 1.45 <0.005 0.32 Expansion 2
and 210.0 296.5 86.5 1.36 6.74 <0.005 1.37 Expansion 2
(including) 212.5 230.5 18.0 4.53 23.3 <0.005 4.78 Expansion 2
30-1237 114.3 158.0 43.7 0.41 2.56 <0.005 0.42 Expansion 1
and 196.3 277.5 81.2 0.50 4.47 0.021 0.58 Expansion 1
(including) 217.0 222.0 5.00 2.29 16.4 0.039 2.44 Expansion 1
and 442.7 489.0 46.3 0.58 5.21 0.143 1.08 Expansion 2
(including) 445.9 453.5 7.60 2.38 20.3 0.116 2.79 Expansion 2
30-1238 64.0 96.0 32.0 0.23 2.18 <0.005 0.23 Expansion 1
and 112.5 162.0 49.5 0.30 1.93 <0.005 0.30 Expansion 2
30-1239 86.0 162.0 76.0 0.31 1.86 <0.005 0.31 Expansion 2
and 203.2 267.0 63.8 0.98 4.08 <0.005 0.99 Expansion 2
(including) 208.9 225.0 16.1 2.54 8.98 0.006 2.57 Expansion 2
30-1240 9.5 72.1 62.6 0.21 1.72 <0.005 0.21 Infill
and 138.0 268.5 130.5 0.28 2.84 <0.005 0.29 Both
30-1241 96.0 138.0 42.0 0.25 1.75 <0.005 0.25 Expansion 1
and 183.0 237.0 54.0 0.44 2.76 <0.005 0.45 Expansion 1
30-1242 29.0 49.0 20.0 0.17 2.06 <0.005 0.17 Expansion 2
and 148.7 178.5 29.8 0.24 2.25 <0.005 0.24 Expansion 2
and 320.0 361.5 41.5 0.39 2.89 0.005 0.40 Expansion 2
30-1243 94.5 306.0 211.5 0.59 2.78 0.005 0.61 Expansion 2
(including) 219.0 247.5 28.5 2.31 11.8 0.023 2.40 Expansion 2
30-1244 69.0 149.0 80.0 0.29 2.46 <0.005 0.29 Both
and 236.5 279.0 42.5 0.38 2.07 <0.005 0.38 Expansion 2
30-1245 15.0 32.0 17.0 0.24 2.49 <0.005 0.25 Infill
and 75.0 276.0 201.0 0.33 2.88 <0.005 0.34 Infill
and 315.0 339.0 24.0 0.68 5.94 <0.005 0.69 Infill
30-1246 71.0 412.5 341.5 0.26 1.94 0.008 0.29 Infill
and 522.0 642.0 120.0 0.32 2.62 0.017 0.37 Infill
30-1247 118.5 144.0 25.5 0.20 1.68 <0.005 0.20 Infill
and 287.6 345.5 57.9 0.31 3.37 <0.005 0.32 Infill

* See explanatory notes below on copper equivalent values and Quality Assurance/Quality Controls.
** Infill refers to intercepts within the current MRE model; Expansion 1 refers to in-pit intercepts outside of the current MRE model; Expansion 2 refers to out-of-pit intercepts outside of the current MRE model. “Both” indicates drill holes that have contiguous shallower infill as well as deeper in-pit expansion intercepts.

Additional comments

Drill holes 30-1236, 30-1239 and 30-1243, all located on the north slope of Needle Mountain, are expansion holes that threaded through pillars of the C Zone underground workings, intersecting significantly higher grades around and within the C Zone skarn horizon. Drill hole 30-1238 also targeted the C Zone horizon but failed to intersect the pillar and stopped in a stope.

Drill holes 30-1237, located near Copper Brook at the base of Needle Mountain, is also an expansion hole that threaded through a pillar of the C Zone underground workings, intersecting higher grades around and within the C Zone skarn horizon (81.2 metres averaging 0.50% Cu and 4.47 g/t Ag), and also at deeper levels (below the floor of the 2026 Whittle pit model) at the level of the E zone skarn horizon (46.3 metres averaging 0.58% Cu and 5.21 g/t Ag). Unusually high molybdenum grades (0.143% Mo) were also obtained in the latter horizon.

Drill hole 30-1244, located on the north slope of Needle Mountain, is an expansion hole that targeted the eastern margin of the C Zone underground workings, just outside the skarn alteration zone, returning significant intersections at two levels between the B Zone and C Zone horizons.

Drill hole 30-1242 is located near the southern margin of the Needle Mountain pit, approximately 730 m southwest of the limit of the 2026 MRE model, and tested an area where little mineralization was expected from historical drilling, yielding three significant mineralized intersections.

Drill holes 30-1240, 30-1241, 30-1245, 30-1246 and 30-1247, all located near Copper Brook at the southern portion of the 2026 MRE model, are infill holes with 30-1241 and 30-1247 being located in the margins of the 2026 MRE model. Grades and lengths of mineralized intersections are in line with the 2026 MRE block model.

Mineralization at Gaspé Copper is of porphyry copper/skarn type and occurs as disseminations and stockworks of chalcopyrite with pyrite or pyrrhotite and minor bornite and molybdenite. One prograde and at least five retrograde vein/stockwork mineralizing events have been recognized at Copper Mountain, which overprint earlier, stratiform, carbonate replacement skarn and porcellanite-hosted mineralization throughout the Gaspé Copper system. Porcellanite is a historical mining term used to describe bleached, pale green to white potassic-altered hornfels. Subvertical stockwork mineralization dominates at Copper Mountain whereas prograde bedding-parallel mineralization, which is mostly stratigraphically controlled, dominates in the area of lower Copper Mountain, Needle Mountain, Needle East, and Copper Brook. High molybdenum grades (up to 0.5% Mo) were locally obtained in both the C Zone and E Zone skarns away from Copper Mountain.

Table 2: Drill hole locations

DDH No. Azimuth (°) Dip (°) Length (m) UTM E UTM N Elevation
30-1236* 242 -88 351 315464 5425459 718
30-1237 0 -90 558 315852 5425668 572
30-1238 0 -90 210 315682 5425488 662
30-1239 133 -88 357 315629 5425439 691
30-1240 260 -75 357 316271 5425402 611
30-1241 164 -82 244 316037 5425798 563
30-1242 68 -77 384 315583 5424894 835
30-1243 0 -90 360 315561 5425586 647
30-1244** 0 -90 459 315745 5425386 678
30-1245 0 -90 354 316567 5425733 577
30-1246 0 -90 648 316242 5425833 587
30-1247 0 -90 387 316642 5425390 615

*Extended hole 30-1037 – results are for total length of both holes
**Extended hole 30-1035 – results are for total length of both holes

The 2022 to 2024 Osisko Metals drill programs were focused on defining open-pit resources within the Copper Mountain stockwork mineralization (see May 6, 2024 MRE press release). Extending the resource model south of Copper Mountain into the poorly-drilled prograde skarn/porcellanite portion of the system subsequently led to a significantly increased resource, mostly in the Inferred category (see November 14, 2024 MRE press release), and additional drilling in 2025 led to an additional significant increase in resources, mostly in the Measured and Indicated categories (see April 14, 2026 MRE press release).

The current drill program is designed to convert the bulk of the remaining 2026 MRE Inferred resources to Measured and Indicated categories, as well as test the expansion of the overall resource laterally to the west, and to the south/southwest towards Needle East and Needle Mountain respectively.

Explanatory note regarding copper-equivalent grades

Copper Equivalent (CuEq) grades are presented for illustrative purposes only to express the combined value of copper, molybdenum, and silver as a single copper grade. CuEq grades are calculated using long-term metal prices of US$4.50/lb copper, US$20.00/lb molybdenum, and US$45.00/oz silver, and incorporate assumptions for metallurgical recoveries, payable metal factors, smelting and refining charges, transportation costs, and royalties. Hence the CuEq calculation is essentially based on net smelter return (NSR) values. NSR for each metal is estimated by applying metallurgical recoveries, payable factors, metal prices, and applicable smelting, refining, transportation, and penalty charges to the in-situ metal grades. CuEq grades are derived using a linear regression relationship established between copper grade and copper NSR, and then calculated by substituting total NSR (Cu + Mo + Ag) for copper NSR in the regression equation. The simplified formula is expressed as CuEq (%) = Cu (%) + 3.40327 × Mo (%) + 0.00008 × Ag (g/t)

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Mr. Bernard-Olivier Martel, P. Geo. (OGQ 492), an independent “qualified person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

Quality Assurance / Quality Control

Mineralized intervals reported herein are calculated using an average 0.12% CuEq lower cut-off over contiguous 20-metre intersections (shorter intervals as the case may be at the upper and lower limits of reported intervals). Intervals of 10 metres or less are generally not reported unless considered material.   True widths are estimated at 80 – 90 % of the reported core length intervals.

Osisko Metals adheres to a strict QA/QC program for core handling, sampling, sample transportation and analyses, including insertion of blanks and standards in the sample stream. Drill core is drilled in HQ or NQ diameter and securely transported to its core processing facility on site, where it is logged, cut and sampled. Samples selected for assay are sealed and shipped to ALS Canada Ltd.’s preparation facility in Sudbury. Sample preparation details (code PREP-31DH) are available on the ALS Canada website. Pulps are analyzed at the ALS Canada Ltd. facility in North Vancouver, BC. All samples are analyzed by four acid digestion followed by both ICP-AES and ICP-MS for Cu, Mo and Ag.

About Osisko Metals

Osisko Metals Incorporated is a Canadian exploration and development company creating value in the critical metals sector, with a focus on copper and zinc. The Company acquired a 100% interest in the past-producing Gaspé Copper mine from Glencore Canada Corporation in July 2023. The Gaspé Copper mine site is located near Murdochville in Québec’s Gaspé Peninsula. The Company is currently focused on resource expansion of the Gaspé Copper deposits, with current pit-constrained Measured and Indicated Mineral Resources of 1.83 Bt averaging 0.32% CuEq and Inferred Mineral Resources of 239 Mt averaging 0.46% CuEq (in compliance with NI 43-101). For more information, see Osisko Metals’ April 14, 2026 news release entitled “Osisko Metals Announces Significant Increase in Mineral Resource at Gaspé Copper”. Gaspé Copper hosts the largest undeveloped copper resource in eastern North America, strategically located near existing infrastructure in the mining-friendly province of Québec.

In addition to the Gaspé Copper project, the Company is working with Appian Capital Advisory LLP through the Pine Point Mining Limited joint venture to advance one of Canada‘s largest past-producing zinc mining camps, the Pine Point project, located in the Northwest Territories. The current mineral resource estimate for the Pine Point project consists of Indicated Mineral Resources of 49.5 Mt averaging 5.52% ZnEq and Inferred Mineral Resources of 8.3 Mt averaging 5.64% ZnEq (in compliance with NI 43-101). For more information, see Osisko Metals‘ June 25, 2024 news release entitled “Osisko Metals releases Pine Point mineral resource estimate: 49.5 million tonnes of indicated resources at 5.52% ZnEq”. The Pine Point project is located on the south shore of Great Slave Lake, NWT, close to infrastructure, with paved road access, an electrical substation and 100 kilometres of viable haul roads.

For further information on this news release, visit www.osiskometals.com or contact:

Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “potential”, “feasibility”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: the tax treatment of the FT Units; the timing of incurring the Qualifying Expenditures and the renunciation of the Qualifying Expenditures; the ability to advance Gaspé Copper to a construction decision (if at all); the ability to increase the Company’s trading liquidity and enhance its capital markets presence; the potential re-rating of the Company; the ability for the Company to unlock the full potential of its assets and achieve success; the ability for the Company to create value for its shareholders; the advancement of the Pine Point project; the anticipated resource expansion of the Gaspé Copper system and Gaspé Copper hosting the largest undeveloped copper resource in eastern North America.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of copper and zinc; the timing and results of exploration and drilling programs; the accuracy of mineral resource estimates; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/35a75f62-b952-4938-bcbe-8b151cf19b88
https://www.globenewswire.com/NewsRoom/AttachmentNg/794a0884-2a24-4e36-be39-d71b9d9d52b7

Saudi Aramco win adds orders beyond the Company’s long-term agreement; US$2.3 million Pertamina Hulu Rokan order builds on momentum under existing 3-year supply contract

SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) — OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today announced new orders totaling US$9.4 million from Saudi Aramco and Pertamina Hulu Rokan. The US$7.1 million Saudi Aramco order is in addition to call-off orders placed under the parties’ long-term supply agreement, including a US$11 million order for specialty connectors and pipes in March 2026.

Due to specific technical and operational requirements, Saudi Aramco’s order for specialty connectors and pipes fell outside the scope of the parties’ long-term agreement and was put out to tender. OMS Oilfield Services Arabia Ltd. (“OMS Saudi”) won the US$7.1 million order through the competitive tender process, highlighting the Company’s 15-year track record of manufacturing expertise, agility and speed in one of the world’s most technically demanding upstream markets. Deliveries are expected to take place in January 2027.

PT OMS Oilfield Services (“OMS Indonesia”) received a US$2.3 million order for surface wellheads and Christmas trees from Pertamina Hulu Rokan under its existing three-year supply contract with the operator. The order supports Pertamina Hulu Rokan’s continuing effort to meet production demand and follows a US$1.3 million extension to the same contract, announced in March 2026, after demand exceeded the original contract value. The products will be manufactured at OMS’s Duri facility in Indonesia, with deliveries expected in March 2027.

Mr. How Meng Hock, Chairman and Chief Executive Officer of OMS, commented, “Winning this US$7.1 million order in an open tender demonstrates both Saudi Aramco’s confidence in our products and the certifications and delivery record OMS Saudi has built in the Kingdom over 15 years. In Indonesia, the new Pertamina Hulu Rokan order reflects growing regional demand, validating our strategy of diversifying beyond our core Saudi Arabian market. With a debt-free balance sheet and strategically located manufacturing facilities across the Asia Pacific and MENA regions, we are well-positioned to continue competing for new business and expanding our customer base.”

About OMS Energy Technologies Inc.

OMS Energy Technologies Inc. (NASDAQ: OMSE) is a growth-oriented manufacturer of surface wellhead systems (SWS) and oil country tubular goods (OCTG) for the oil and gas industry. Serving both onshore and offshore exploration and production operators, OMS is a trusted engineered solutions supplier across six vital jurisdictions in the Asia Pacific, Middle Eastern and North African (MENA) regions. The Company’s 11 strategically located manufacturing facilities in key markets ensure rapid response times, customized technical solutions and seamless adaptation to evolving production and logistics needs. Beyond its core SWS and OCTG offerings, OMS also provides premium threading services to maximize operational efficiency for its customers.

For more information, please visit ir.omsos.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

OMS Energy Technologies Inc.
Investor Relations
Email: ir@omsos.com

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: omsos@thepiacentegroup.com

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.

The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis.

Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality.

The collaboration will also compare enzymatically synthesized fragments with conventional solid-phase oligonucleotide synthesis (SPOS), evaluating purity, product quality, and ligation performance. The results will allow the innovator to assess the technology’s potential for future clinical development programs.

Alison Moore, PhD., President and CEO at Codexis, said: “This agreement is an important next step in bringing our latest ECO Synthesis capabilities to a customer. Working with a pioneer in the siRNA field offers an exciting opportunity to demonstrate how ECO Synthesis can deliver stereochemical control, which may offer both superior product quality and therapeutic performance to an innovator’s pipeline over assets produced using traditional solid phase chemistry methods.”

Codexis continues to advance the ECO Synthesis Manufacturing Platform as part of its strategy to industrialize scalable manufacturing solutions for complex oligonucleotide therapeutics.

About Codexis, Inc.

Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the Company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Georgia Erbez
+1 (650) 421-8100
ir@codexis.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.